3-hydroxy Darifenacin

• CAT Number: I020885
• CAS Number: 206048-82-0
• Molecular Formula: C28H30N2O3
• Molecular Weight: 442.56
• Purity: 95%
• Synonyms: 3-hydroxy Darifenacin, UK 148993
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 2-((3S)-1-(2-(3-hydroxy-2,3-dihydrobenzofuran-5-yl)ethyl)pyrrolidin-3-yl)-2,2-diphenylacetamide
• InChI: InChI=1S/C28H30N2O3/c29-27(32)28(21-7-3-1-4-8-21,22-9-5-2-6-10-22)23-14-16-30(18-23)15-13-20-11-12-26-24(17-20)25(31)19-33-26/h1-12,17,23,25,31H,13-16,18-19H2,(H2,29,32)/t23-,25?/m1/s1
• InChIKey: MQEQBFMESJKUBQ-XQZUBTRRSA-N
• SMILES: NC(C(C1=CC=CC=C1)(C2=CC=CC=C2)[C@H]3CN(CCC4=CC=C(OCC5O)C5=C4)CC3)=O

3-hydroxy Darifenacin is a metabolite of darifenacin. It is an antagonist of M1-5 muscarinic receptors.

Reference

1. Beaumont, K.C., Cussans, N.J., Nichols, D.J., et al. Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. Xenobiotica 28(1), 63-75 (1998).
2. Kerbusch, T., Wählby, U., Milligan, P.A., et al. Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. Br. J. Clin. Pharmacol. 56(6), 639-652 (2003).
3. Mansfield, K.J., Chandran, J.J., Vaux, K.J., et al. Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. J. Pharmacol. Exp. Ther. 328(3), 893-899 (2009).